Back

Maximally tolerated guideline-directed medical therapy and barriers to optimization in patients with heart failure with reduced ejection fraction: The COAPT trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Heart failure pharmacology Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Zachary Cox

Lipscomb University College of Pharmacy, Nashville (United States of America)

6 More presentations in this session

Presentation thumbnail
Adherence and discontinuation of optimal heart failure therapies according to age
Miss C. Garred (Herlev, DK)
Abstract Slides
Presentation thumbnail
Real-world eligibility for vericiguat according to trial, guideline, and labelling eligibility criteria: data from the Swedish Heart Failure Registry
Mr V. Nguyen (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Efficacy of sodium glucose cotransporter 2 inhibitors for heart failure with preserved and mildly reduced ejection fraction: a systematic review and meta-analysis
Doctor K. Rivera (Manila, PH)
Abstract Slides
Presentation thumbnail
Compliance to guideline-recommended pharmacotherapy in patients with heart failure, 2014 to 2020
Doctor K. Odegaard (Oslo, NO)
Abstract Slides
Presentation thumbnail
Comparative efficacy of novel drugs as an addition to guideline-directed medical therapy for heart failure with reduced ejection fraction: a network meta-analysis of randomised controlled trials
Mr T. Suebsaicharoen (Bangkok, TH)
Abstract Slides

Access the full session

Session thumbnail
Heart failure pharmacology

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources